HHS Secretary Leavitt to visit HIV/AIDS projects in Cote d'Ivoire

NewsGuard 100/100 Score

HHS Secretary Mike Leavitt on Wednesday is scheduled to arrive in Cote d'Ivoire, where he will visit projects aimed at fighting HIV/AIDS, malaria and other diseases, AFP/Google.com reports.

Leavitt will spend two days in the country, which receives funding from the President's Emergency Plan for AIDS Relief. PEPFAR has allocated $120 million for Cote d'Ivoire's HIV/AIDS efforts from April 2008 to March 2009, according to the U.S. embassy in Abidjan. The $120 million represents a 43% increase in funding compared with the previous year, AFP/Google.com reports. According to the embassy, a second five-year HIV/AIDS project likely will be approved by the government this year (AFP/Google.com, 8/11).

CDC Director Julie Gerberding and coordinator of the President's Malaria Initiative Tim Ziemer are traveling with Leavitt, and they also will visit Ethiopia and Mali. The officials will meet with government representatives in the three countries; visit hospitals, research centers and clinics; and travel to rural communities. They also will meet with religious leaders and look at the role of faith-based organizations in health care (HHS release, 8/8).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough study offers hope for an effective HIV cure